Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387320 | 1.00 | HSD17B10 (0.55) | HSD17B10MAPTCYP2C9CYP3A4KCNH2 | |
| SCHEMBL23629004 | 0.85 | CYP2C19 (0.55) | HSD17B10MAPTCYP2C9CYP3A4KCNH2 | |
| SCHEMBL28570422 | 0.85 | HSD17B10 (0.51) | HSD17B10MAPTCYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL642545 | 0.84 | CYP3A4 (0.50) | HSD17B10MAPTCYP2C9CYP3A4KCNH2 | |
| SCHEMBL2920222 | 0.84 | CYP2C9 (0.46) | HSD17B10MAPTCYP2C9CYP3A4KCNH2 | |
| SCHEMBL11589979 | 0.84 | ALDH1A1 (0.54) | HSD17B10MAPTCYP2C9CYP3A4KCNH2 | |
| SCHEMBL2275450 | 0.84 | LMNA (0.51) | HSD17B10MAPTCYP2C9CYP3A4KCNH2 | |
| SCHEMBL9957845 | 0.84 | PIK3CA (0.44) | MAPTALDH1A1MEN1KMT2AHDAC1 | |
| SCHEMBL26962466 | 0.83 | HSD17B10 (0.60) | HSD17B10MAPTCYP3A4ALDH1A1KDM4E | |
| SCHEMBL9952440 | 0.82 | KDM4E (0.42) | MAPTALDH1A1MEN1KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-3650449-B1 | FXR RECEPTOR AGONIST | XUANZHU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3650449-B1 | FXR RECEPTOR AGONIST | XUANZHU BIOPHARMACEUTICAL CO LTD (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | IRM LLC (BM) | 2013-10-03 | — | — | US | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| EP-1037632-B1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6825355-B2 | FOR THERAPY OF IMMUNOLOGIC DISORDERS SUCH AS TRANSPLANT REJECTION, RHEUMATOID ARTHRITIS. MULTIPLE SCLEROSIS, INFLAMMATORY BOWEL DISEASE, LUPUS, GRAFT VS. HOST DISEASE | BRISTOL-MYERS SQUIBB CO. | 2004-11-30 | — | — | US | disclosed |
| EP-1037632-A4 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-08-21 | — | — | EP | disclosed |
| CN-1290165-A | Benzothiazole Protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2001-04-04 | — | — | CN | disclosed |
| EP-1037632-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999024035-A1 | BENZOTHIAZOLE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | HSD17B10 2510/4885MAPT 4666/4885CYP2C9 566/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | HSD17B10 770/4885MAPT 4700/4885CYP2C9 1237/4885 |
| US-20130261108-A1 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS | NR1H4, SLC10A1, GPBAR1 | HSD17B10 297/4885MAPT 4386/4885CYP2C9 462/4885 |
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | HSD17B10 1225/4885MAPT 4772/4885CYP2C9 2357/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | HSD17B10 770/4885MAPT 4700/4885CYP2C9 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.